BioCryst Pharmaceuticals BCRX Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's unrealized gains (losses) on available-for-sale securities?
- BioCryst Pharmaceuticals (BCRX) reported unrealized gains (losses) on available-for-sale securities of -$344K in Q1 2026.
- How has BioCryst Pharmaceuticals's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- BioCryst Pharmaceuticals's unrealized gains (losses) on available-for-sale securities decreased by 121.9% year-over-year, from -$155K to -$344K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- The change in the fair value of investment securities classified as available-for-sale that has not yet been realized through a sale. This reflects market-driven fluctuations in the value of the company's liquid investment portfolio.